

AccuVert™ HIV-1 Seroconversion Panel

0600-0240

INTENDED USE

The AccuVert™ HIV-1 Seroconversion Panel 0600-0240 is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HIV-1 test methods. Characterized samples and comprehensive data are provided for comparative analysis. For Research Use Only. Not for use in diagnostic procedures.

PRODUCT DESCRIPTION

This product is a 5-member HIV seroconversion panel. Panel members represent serial bleeds from a single donor during the development and progression of an HIV-1 infection. Panel members consist of undiluted, naturally occurring plasma samples. Each sample represents a single collection event. No preservatives were added.

Material Number: 0600-0240, 1 vial per member
5 members, 1.0 mL per vial

STORAGE

Panel members should be stored frozen at -70°C or colder. LGC SeraCare recommends that the panel members be divided into smaller aliquots for ease in repeated testing and to avoid multiple freeze-thaw cycles. If turbidity or particulate matter is observed, the samples should be centrifuged in accordance with each test kit manufacturer's instructions for sample preparation.

INTERPRETATION OF RESULTS

The Data Sheet for AccuVert HIV-1 Seroconversion Panel 0600-0240 is available at www.seracare.com. The Data Sheet lists results for panel members generated using commercially available screening, monitoring and confirmatory test methods. Tests were performed at sLGC SeraCare or at recognized reference laboratories (RL) by individuals who routinely use these procedures. Information regarding specific test methods is available on the Data Sheet. Data Sheets are updated when new data are available.

LIMITATIONS

AccuVert HIV-1 Seroconversion Panel 0600-0240 is offered for research use only. Not for use in diagnostic procedures. Data are provided for informational purposes. LGC SeraCare Life Sciences does not claim that others can duplicate test results exactly.

PRECAUTIONS

These materials have not been treated and should be considered biohazardous. Follow Universal Precautions¹. Some panel members were found positive by tests for anti-HIV-1/2. The units that make up this panel were tested and found negative for anti-HCV and HBsAg. This does not ensure the absence of these or other human pathogens.

Do not pipette by mouth. Do not smoke, eat, or drink in areas where specimens are handled.

These materials should be disposed of in a manner that will inactivate pathogenic agents.

REFERENCES

1. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.

For assistance, contact LGC Clinical Diagnostics at 508.244.6400.

The package insert for this panel can be found at www.seracare.com.

A printed copy of the package insert or data sheet may be requested by email at CDx-Info@LGCGroup.com or by phone at 508.244.6400.